Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 188011, Ly
2. 2' Deoxy 2' Difluorocytidine
3. 2' Deoxy 2',2'' Difluorocytidine 5' O Monophosphate
4. 2',2'-dfdc
5. 2',2'-difluoro-2'-deoxycytidine
6. 2',2'-difluorodeoxycytidine
7. 2'-deoxy-2',2''-difluorocytidine-5'-o-monophosphate
8. 2'-deoxy-2'-difluorocytidine
9. Dfdcyd
10. Gemcitabine
11. Gemcitabine, (alpha-d-threo-pentofuranosyl)-isomer
12. Gemcitabine, (beta-d-threo-pentafuranosyl)-isomer
13. Gemcitabine, (d-threo-pentafuranosyl)-isomer
14. Gemicitabine
15. Gemzar
16. Hydrochloride, Gemcitabine
17. Ly 188011
18. Ly-188011
1. Gemcitabine Hcl
2. 122111-03-9
3. Gemzar
4. Ly188011 Hydrochloride
5. Gemcitabine (hydrochloride)
6. 2'-deoxy-2',2'-difluorocytidine Monohydrochloride
7. Cytidine, 2'-deoxy-2',2'-difluoro-, Monohydrochloride
8. Dfdc
9. 4-amino-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one Hydrochloride
10. Gemcitabine (as Hydrochloride)
11. U347pv74il
12. Chebi:31647
13. 2',2'-difluoro-2'-deoxycytidine Hydrochloride
14. Ly-188011 Hydrochloride
15. Ly-188011
16. 122111-03-9 (hcl)
17. Dsstox_cid_27827
18. Dsstox_rid_82590
19. Dsstox_gsid_47849
20. 2'-deoxy-2',2'-difluorocytidine Hydrochloride
21. 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
22. Dizirconium Silicide
23. Cas-122111-03-9
24. Gemcitabine Hydrochloride [usan]
25. Gemcitabine Hcl (gemzar)
26. Ly 188011
27. Unii-u347pv74il
28. Mfcd01735988
29. Ncgc00168784-01
30. Gemzar (tn)
31. Infugem
32. Gemcitabine Hydrochloride [usan:usp]
33. Inno-d07001
34. Schembl4366
35. Chembl1637
36. Ly 188011 Hydrochloride
37. Mls003915643
38. Gemcitabine Hydrochloride,(s)
39. Dtxsid3047849
40. Ex-a837
41. 2'-deoxy-2',2'-difluorocytidine Monohydrochloride (beta-isomer)
42. Act06731
43. Hy-b0003
44. Ly-188011 . Hcl
45. Tox21_112644
46. Bdbm50247964
47. Gemcitabine Hydrochloride (jan/usp)
48. S1149
49. Gemcitabine Hydrochloride [mi]
50. Akos015999730
51. Tox21_112644_1
52. Ccg-267459
53. Cs-0755
54. Gemcitabine Hcl (gemzar,ly188011)
55. Gemcitabine Hydrochloride [jan]
56. 2'-deoxy-2',2'-difluorocytidine Hcl
57. Gemcitabine Hydrochloride [mart.]
58. Gemcitabine Hydrochloride [vandf]
59. Ncgc00168784-03
60. As-13656
61. Bg164501
62. Gemcitabine Hydrochloride [usp-rs]
63. Gemcitabine Hydrochloride [who-dd]
64. Smr000469146
65. Gemcitabine Hydrochloride, >=98% (hplc)
66. Gemcitabine Hydrochloride,gemzar, Ly-188011
67. D01155
68. Gemcitabine Hydrochloride [ep Monograph]
69. Gemcitabine Hydrochloride [orange Book]
70. 2'-deoxy-2',2'-difluorocytidine, Hydrochloride
71. Gemcitabine Hydrochloride [usp Monograph]
72. 111g039
73. W-60402
74. (+)-2'-deoxy-2',2'-difluorocytidine Hydrochloride
75. J-700175
76. Q27114559
77. 2'-deoxy-2',2'-difluorocytidine Monohydrochloride (.beta.-isomer)
78. Gemcitabine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
79. Gemcitabine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
80. (2'r,4'r,5'r)-4-amino-1-(3,3-difluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyridin-2-one Hydrochloride
81. 4-amino-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-one Hydrochloride
82. 4-amino-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-onehydrochloride
1. Gemcitabine Free Base
Molecular Weight | 299.66 g/mol |
---|---|
Molecular Formula | C9H12ClF2N3O4 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 299.0484399 g/mol |
Monoisotopic Mass | 299.0484399 g/mol |
Topological Polar Surface Area | 108 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 426 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Gemcitabine hydrochloride |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 200mg base/vial; 1gm/26.3ml (38mg/ml); 2gm/52.6ml (38mg/ml); 200mg/5.26ml (38mg/ml); eq 1gm base/vial |
Market Status | Prescription |
Company | Hospira; Jiangsu Hansoh Pharm; Fresenius Kabi Oncol; Accord Hlthcare; Cipla; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Teva Pharms; Fresenius Kabi Usa; Onco Therapies; Hameln Rds Gmbh; Luitpold; Sagent Pharms; Dr Reddys Labs |
2 of 4 | |
---|---|
Drug Name | Gemzar |
PubMed Health | Gemcitabine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 200mg base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Lilly |
3 of 4 | |
---|---|
Drug Name | Gemcitabine hydrochloride |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 200mg base/vial; 1gm/26.3ml (38mg/ml); 2gm/52.6ml (38mg/ml); 200mg/5.26ml (38mg/ml); eq 1gm base/vial |
Market Status | Prescription |
Company | Hospira; Jiangsu Hansoh Pharm; Fresenius Kabi Oncol; Accord Hlthcare; Cipla; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Teva Pharms; Fresenius Kabi Usa; Onco Therapies; Hameln Rds Gmbh; Luitpold; Sagent Pharms; Dr Reddys Labs |
4 of 4 | |
---|---|
Drug Name | Gemzar |
PubMed Health | Gemcitabine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 200mg base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Lilly |
Treatment of urothelial carcinoma
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-06-27
Pay. Date : 2016-06-06
DMF Number : 18857
Submission : 2005-10-11
Status : Active
Type : II
Certificate Number : R1-CEP 2007-075 - Rev 06
Issue Date : 2021-06-18
Type : Chemical
Substance Number : 2306
Status : Valid
Registration Number : 220MF10243
Registrant's Address : 8-2-337, Road No. 3,Banjara Hills,Hyderabad 500 034,TELANGANA,INDIA
Initial Date of Registration : 2008-12-04
Latest Date of Registration : --
Date of Issue : 2022-06-06
Valid Till : 2025-07-07
Written Confirmation Number : WC-0039
Address of the Firm :
Registrant Name : Korea United Pharmaceutical Co., Ltd.
Registration Date : 2012-05-18
Registration Number : 20070928-86-D-51-03(3)
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : CTO - Unit-I, Plot Nos. 137,138,145 & 146, SV Co-Op, Industrial Estate, Bollaram Village, Jinnaram Mandal, Sangareddy District, Telangana - 502 325, INDIA
Certificate Number : R1-CEP 2011-032 - Rev 01
Issue Date : 2017-09-27
Type : Chemical
Substance Number : 2306
Status : Valid
Registration Number : 220MF10259
Registrant's Address : Balmes 85, Atico, 08008 (Barcelona), Spain
Initial Date of Registration : 2008-12-22
Latest Date of Registration : --
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-07
Pay. Date : 2012-11-15
DMF Number : 24893
Submission : 2011-04-26
Status : Active
Type : II
Certificate Number : R0-CEP 2011-117 - Rev 01
Issue Date : 2015-02-05
Type : Chemical
Substance Number : 2306
Status : Withdrawn by Holder
NDC Package Code : 58623-0019
Start Marketing Date : 2010-08-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-04-11
Pay. Date : 2012-12-18
DMF Number : 24136
Submission : 2011-03-04
Status : Active
Type : II
Certificate Number : R1-CEP 2006-222 - Rev 01
Issue Date : 2023-02-23
Type : Chemical
Substance Number : 2306
Status : Valid
Registration Number : 221MF10017
Registrant's Address : 10/80, RAJENDRA GUNJ, RAICHUR-584 102, INDIA
Initial Date of Registration : 2009-01-13
Latest Date of Registration : --
Date of Issue : 2019-07-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0148
Address of the Firm :
NDC Package Code : 82920-701
Start Marketing Date : 2022-08-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Lee Yeon Pharmaceutical Co., Ltd.
Registration Date : 2012-10-05
Registration Number : 20080110-86-D-2-05(2)
Manufacturer Name : Shilpa Medicare Limited
Manufacturer Address : Plot No. 1A & 1A'P', 1B, 2, 2A, 2B, 3A to 3E, 4A, 5A, 4B & 5B Deosugur Industrial Area, Deosugur - 584 170, Dist: Raichur, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19427
Submission : 2006-05-16
Status : Active
Type : II
Certificate Number : CEP 2007-021 - Rev 02
Issue Date : 2024-06-12
Type : Chemical
Substance Number : 2306
Status : Valid
Registration Number : 221MF10018
Registrant's Address : SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, Maharashtra, India
Initial Date of Registration : 2009-01-28
Latest Date of Registration : --
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm :
Registrant Name : Repure Healthcare Co., Ltd.
Registration Date : 2021-07-11
Registration Number : 20210711-86-D-159-24
Manufacturer Name : Sun Pharmaceutical Industries Ltd.
Manufacturer Address : A-7/A-8, MIDC Industrial Area, Ahmednagar 414111, Maharashtra State, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23516
Submission : 2010-02-12
Status : Inactive
Type : II
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2013-08-06
Registration Number : 20130806-86-D-121-18
Manufacturer Name : Euticals SpA
Manufacturer Address : Varese (VA) - Via Valverde 20, Italy.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24278
Submission : 2010-10-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21274
Submission : 2008-01-22
Status : Inactive
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2016-06-27
Pay. Date : 2016-06-06
DMF Number : 18857
Submission : 2005-10-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21274
Submission : 2008-01-22
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-08
Pay. Date : 2012-12-19
DMF Number : 21399
Submission : 2008-04-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18810
Submission : 2005-09-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22229
Submission : 2008-11-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22748
Submission : 2009-04-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-23
Pay. Date : 2012-11-16
DMF Number : 22800
Submission : 2009-05-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22199
Submission : 2008-10-23
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-14
Pay. Date : 2013-11-21
DMF Number : 19053
Submission : 2005-12-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19427
Submission : 2006-05-16
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Farmhispania Group comprises two companies in Spain: Farmhispania in Barcelona and Rolabo in Zaragoza. Since its inception, the group has consistently invested in advanced equipmen...
About the Company : We are a Pharmaceutical Company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to ...
About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...
About the Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 years of development, ...
About the Company : Hoventa Pharma is in the business of manufacturing APIs for over three decades.We offer various kinds of services in addition to supplies of APIs, we undertake long-term contracts ...
About the Company : Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Ph...
About the Company : Established in 2010, Mac-Chem is a NMM Group company. Mac-Chem is focused on oncology and other niche specialty APIs. It supplies quality APIs to the top 15 oncology players in Ind...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody approved in combination with cisplatin and gemcitabine for first-line treatment of metastatic or recurrent nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Loqtorzi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SEC Recommends Approval to Dr Reddy's to Import and Market Anti-cancer Drug Toripalimab
Details : Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody approved in combination with cisplatin and gemcitabine for first-line treatment of metastatic or recurrent nasopharyngeal carcinoma.
Brand Name : Loqtorzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 18, 2024
Details:
IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for pancreatic ductal adenocarcinoma with gemcitabine and nab-paclitaxel.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: IMM-1-104
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Immuneering Granted Orphan Drug Status for IMM-1-104 in Pancreatic Cancer
Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for pancreatic ductal adenocarcinoma with gemcitabine and nab-paclitaxel.
Brand Name : IMM-1-104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Details:
Loqtorzi (toripalimab) is an approved anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Loqtorzi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: TopAlliance Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : TopAlliance Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Junshi Biosciences Gains Toripalimab Approval in India and Hong Kong SAR
Details : Loqtorzi (toripalimab) is an approved anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic nasopharyngeal carcinoma.
Brand Name : Loqtorzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 15, 2024
Details:
GP-2250 (misetionamide) is being evaluated in the early-stage clinical trial studies in combination with gemcitabine for the treatment of panmcreatic cancer.
Lead Product(s): Misetionamide,Gemcitabine
Therapeutic Area: Oncology Brand Name: GP-2250
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2024
Lead Product(s) : Misetionamide,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Panavance Updates on Misetionamide Phase 1 Trial in Pancreatic Cancer
Details : GP-2250 (misetionamide) is being evaluated in the early-stage clinical trial studies in combination with gemcitabine for the treatment of panmcreatic cancer.
Brand Name : GP-2250
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2024
Details:
TAR-200 (gemcitabine) is a DNA polymerase inhibitor. It is under phase 2 clinical evaluation in combination with Cetrelimab for the treatment of BCG unresponsive non-muscle-invasive bladder cancer.
Lead Product(s): Gemcitabine,Cetrelimab
Therapeutic Area: Oncology Brand Name: TAR-200
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2024
Lead Product(s) : Gemcitabine,Cetrelimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
J&J Discontinues Late-Stage Study for Bladder Cancer Drug
Details : TAR-200 (gemcitabine) is a DNA polymerase inhibitor. It is under phase 2 clinical evaluation in combination with Cetrelimab for the treatment of BCG unresponsive non-muscle-invasive bladder cancer.
Brand Name : TAR-200
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 07, 2024
Details:
The net proceeds will be used to fund the clinical development of the company's lead product VCN-01, which is being evaluated for the treatment of Metastatic Pancreatic Ductal Adenocarcinoma.
Lead Product(s): VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Brand Name: VCN-01
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Alliance Global Partners
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 26, 2024
Lead Product(s) : VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alliance Global Partners
Deal Size : $2.5 million
Deal Type : Public Offering
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
Details : The net proceeds will be used to fund the clinical development of the company's lead product VCN-01, which is being evaluated for the treatment of Metastatic Pancreatic Ductal Adenocarcinoma.
Brand Name : VCN-01
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 26, 2024
Details:
Loqtorzi (toripalimab) is an approved anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Loqtorzi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Junshi Biosciences Announces European Commission Approval For Marketing of Toripalimab
Details : Loqtorzi (toripalimab) is an approved anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic nasopharyngeal carcinoma.
Brand Name : Loqtorzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 24, 2024
Details:
VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Lead Product(s): VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Brand Name: VCN-01
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2024
Lead Product(s) : VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theriva Achieves Enrollment Target in Phase 2b of VCN-01 for Metastatic Pancreatic Cancer
Details : VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Brand Name : VCN-01
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 23, 2024
Details:
AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Lead Product(s): AMP945,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: AMP945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2024
Lead Product(s) : AMP945,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer
Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Brand Name : AMP945
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2024
Details:
TAR-200 (gemcitabine) is a DNA polymerase inhibitor. It is under phase 2 clinical evaluation in combination with Cetrelimab for the treatment of BCG unresponsive non-muscle-invasive bladder cancer.
Lead Product(s): Gemcitabine,Cetrelimab
Therapeutic Area: Oncology Brand Name: TAR-200
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2024
Lead Product(s) : Gemcitabine,Cetrelimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Data from TAR-200 Phase 2b Show 84% Response Rate in High-Risk Bladder Cancer
Details : TAR-200 (gemcitabine) is a DNA polymerase inhibitor. It is under phase 2 clinical evaluation in combination with Cetrelimab for the treatment of BCG unresponsive non-muscle-invasive bladder cancer.
Brand Name : TAR-200
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2024
2'-Deoxy-2',2'-difluoro-D-erythro-pentofuranous-1-...
CAS Number : 122111-01-7
End Use API : Gemcitabine
About The Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we...
2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate...
CAS Number : 134877-42-2
End Use API : Gemcitabine
About The Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we...
2’,2’-Difluoro-2’-deoxycyodine-3’,5’-dib...
CAS Number : 134790-39-9
End Use API : Gemcitabine
About The Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we...
2'-Deoxy-2',2'-difluoro-D-erythro-pentofuranous-1-...
CAS Number : 122111-01-7
End Use API : Gemcitabine
About The Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we...
2’,2’-Difluoro-2’-deoxycyodine-3’,5’-dib...
CAS Number : 134877-42-2
End Use API : Gemcitabine
About The Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we...
2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate...
CAS Number : 134790-39-9
End Use API : Gemcitabine
About The Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we...
((2R, 3R)-3-(BENZOLOXY)-4, 4- DIFLUORO-5- OXOTETRA...
CAS Number : 122111-01-7
End Use API : Gemcitabine
About The Company : Dasami Lab Private Limited incorporated with MCA on 24 July 2015. The Dasami Lab Private Limited is listed in the class of pvtltd company and classified as Non ...
[(2R,3R)-3-benzoyloxy-4,4-difluoro-5-oxooxolan-2-y...
CAS Number : 122111-01-7
End Use API : Gemcitabine
About The Company : Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development...
[(2R,3R)-3-benzoyloxy-4,4-difluoro-5-methylsulfony...
CAS Number : 122111-11-9
End Use API : Gemcitabine
About The Company : Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development...
[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-benz...
CAS Number : 134790-39-9
End Use API : Gemcitabine
About The Company : Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 100 mg/ml
Price Per Pack (Euro) : 43.494
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 100 mg/ml
Price Per Pack (Euro) : 197.43
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 100 mg/ml
Price Per Pack (Euro) : 293.77
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 100 mg/ml
Price Per Pack (Euro) : 390.10
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 38 mg/ml
Price Per Pack (Euro) : 43.494
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 38 mg/ml
Price Per Pack (Euro) : 197.43
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 38 mg/ml
Price Per Pack (Euro) : 390.10
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 40 mg/ml
Price Per Pack (Euro) : 43.494
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 40 mg/ml
Price Per Pack (Euro) : 197.43
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 40 mg/ml
Price Per Pack (Euro) : 390.10
Published in :
Country : Norway
RX/OTC/DISCN :
Market Place
Reply
11 Oct 2024
Reply
11 Mar 2024
Reply
24 May 2023
Reply
18 Apr 2023
Reply
11 Jan 2023
Reply
28 Dec 2021
Reply
25 Jun 2021
Reply
09 Feb 2021
Reply
01 Oct 2020
Reply
04 Sep 2020
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?